Cancer Family
Myomatous Neoplasm
CI-CAN-00000282Explore in graph →
Non-malignant151 active trials1 approved drugs38 evidence items
- NCIt
- C214799
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000282Explore in graph →
Clinical trials
755 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02166554 | The Efficacy and Safety Study of a New Cross-linked Hyaluronan Hydrogel in the Reduction of Postsurgical Peritoneal Adhesions(BAP) | completed | Phase 1 / Phase 2 | 216 | BioRegen Biomedical (Changzhou) Co., LtdINDUSTRY | 1 | Jun 18, 2014 | clinicaltrials |
| NCT01816815 | Study in Healthy Tubal Ligated Women to Evaluate Pharmacodynamics, Safety and Pharmacokinetics of BAY1002670 | completed | Phase 1 | 73 | BayerINDUSTRY | 3 | Apr 21, 2014 |
| clinicaltrials |
| NCT00031681 | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00012181 | Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00077454 | Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 | 95 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00101270 | Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00093821 | Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors | completed | Phase 1 | 70 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00837161 | Pilot Study of MRI-Guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids | completed | Phase 1 / Phase 2 | 11 | Philips HealthcareINDUSTRY | 1 | Dec 4, 2012 | clinicaltrials |
| NCT00132158 | ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors | completed | Phase 1 | 19 | St. Jude Children's Research HospitalOTHER | 1 | Apr 17, 2012 | clinicaltrials |
| NCT00436657 | Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer | completed | Phase 1 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 2, 2012 | clinicaltrials |
| NCT00361036 | Comparison Study in the Treatment of Uterine Fibroids Uterine Fibroid Embolization Using BeadBlock™ Embolic Agent | completed | Phase 1 | 44 | Worthington-Kirsch, Robert L., M.D.INDIV | 1 | Apr 18, 2011 | clinicaltrials |
| NCT00543790 | Study Evaluating PRA-027 Multiple Ascending Doses In Cycling And Postmenopausal Women | completed | Phase 1 | 48 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Oct 28, 2010 | clinicaltrials |
| NCT00444704 | Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRA-027 Administered to Healthy Japanese Females | completed | Phase 1 | — | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Jul 10, 2009 | clinicaltrials |
| NCT00187109 | Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy | completed | Phase 1 / Phase 2 | 40 | St. Jude Children's Research HospitalOTHER | 1 | Apr 10, 2008 | clinicaltrials |
| NCT00427544 | Study of the Safety, Tolerability, and PK of PRA-027 Administered to Women of Nonchildbearing Potential | completed | Phase 1 | — | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Dec 5, 2007 | clinicaltrials |
| NCT00562471 | Safety and Efficacy Study of a Hydrogel, Applied Following Removal of Myomas During Gynecologic Surgery, Administered for the Prevention/Reduction of Postoperative Adhesion Formation | completed | Phase 1 / Phase 2 | 76 | Angiotech PharmaceuticalsINDUSTRY | 3 | Nov 22, 2007 | clinicaltrials |
Data updated 23 days agoSource updated Jun 18, 2014source: clinicaltrials